

Title (en)
ACTIVE AGENT FOR COMBATING TUMOURS

Publication
EP 0285906 A3 19900207 (DE)

Application
EP 88104603 A 19880323

Priority
DE 3710806 A 19870331

Abstract (en)
[origin: EP0285906A2] The use of norverapamil alone or in combination with carcinostatics in tumour therapy is described.

IPC 1-7
A61K 31/275

IPC 8 full level
A61K 31/275 (2006.01); **A61K 31/277** (2006.01); **A61K 31/475** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP US)
A61K 31/275 (2013.01 - EP US); **A61K 31/475** (2013.01 - EP US); **A61P 35/00** (2017.12 - EP)

C-Set (source: EP US)
1. **A61K 31/475 + A61K 31/275**
2. **A61K 31/475 + A61K 2300/00**

Citation (search report)

- [E] EP 0268100 A1 19880525 - BASF AG [DE]
- [X] EP 0075823 A2 19830406 - KNOLL AG [DE]
- [X] DIALOG 0160440, Dehaen Drug Data 1980-1988, Subfile: Dir, Pharma 1982; "Norverapamil"

Cited by
WO9100091A1; WO9001317A1

Designated contracting state (EPC)
AT BE CH DE ES FR GB IT LI NL

DOCDB simple family (publication)
EP 0285906 A2 19881012; EP 0285906 A3 19900207; EP 0285906 B1 19930811; AT E92758 T1 19930815; DE 3710806 A1 19881027; DE 3883044 D1 19930916; ES 2058161 T3 19941101; JP S63258414 A 19881025; US 4935445 A 19900619

DOCDB simple family (application)
EP 88104603 A 19880323; AT 88104603 T 19880323; DE 3710806 A 19870331; DE 3883044 T 19880323; ES 88104603 T 19880323; JP 6748188 A 19880323; US 17436688 A 19880328